Show simple item record

dc.contributor.authorSmrke, A
dc.contributor.authorThway, K
dc.contributor.authorH Huang, P
dc.contributor.authorJones, RL
dc.contributor.authorHayes, AJ
dc.date.accessioned2021-11-25T14:45:30Z
dc.date.available2021-11-25T14:45:30Z
dc.date.issued2021-09-01
dc.identifier.citationFuture oncology (London, England), 2021, 17 (27), pp. 3627 - 3636
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4902
dc.identifier.eissn1744-8301
dc.identifier.doi10.2217/fon-2021-0030
dc.description.abstractSolitary fibrous tumor (SFT) is a rare soft tissue sarcoma subtype which mainly affects adults in the fifth and sixth decades of life. Originally part of a spectrum of tumors called hemangiopericytomas, classification has been refined such that SFTs now represent a distinct subtype. The identification of NAB2-STAT6 fusion in virtually all SFTs has further aided to define this rare subgroup. SFTs have a spectrum of behavior from benign to malignant, with evidence suggesting risk of metastases related to age at diagnosis, extent of necrosis, mitotic rate and tumor size. The standard treatment for localized disease is surgical excision with or without radiotherapy. Retrospective and prospective evidence suggests antiangiogenic treatment is effective for unresectable disease. Further translational work is required to understand the biology driving the differential behavior and identify more effective treatments for patients with metastatic disease.
dc.formatPrint-Electronic
dc.format.extent3627 - 3636
dc.languageeng
dc.language.isoeng
dc.publisherFUTURE MEDICINE LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleSolitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma.
dc.typeJournal Article
dcterms.dateAccepted2021-04-30
rioxxterms.versionVoR
rioxxterms.versionofrecord10.2217/fon-2021-0030
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFuture oncology (London, England)
pubs.issue27
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume17
pubs.embargo.termsNot known
icr.researchteamSarcoma Clinical Trials (R Jones)
icr.researchteamMolecular and Systems Oncology
icr.researchteamSarcoma and Melanoma Surgery
dc.contributor.icrauthorHuang, Paul
dc.contributor.icrauthorJones, Robin
dc.contributor.icrauthorHayes, Andrew


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0